Clene (CLNN) Set to Announce Quarterly Earnings on Thursday

Clene (NASDAQ:CLNN) will likely be issuing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.46) per share and revenue of $0.07 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 7:00 AM ET.

Clene (NASDAQ:CLNN) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.50. The business had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.07 million. On average, analysts expect Clene to post ($1.05) EPS for the current fiscal year and ($1.17) EPS for the next fiscal year.

Clene Stock Up 10.9%

CLNN opened at $4.38 on Tuesday. Clene has a 52 week low of $3.02 and a 52 week high of $10.84. The business has a fifty day simple moving average of $3.90 and a 200-day simple moving average of $5.13. The firm has a market cap of $56.90 million, a P/E ratio of -1.68 and a beta of 1.04.

Wall Street Analyst Weigh In

CLNN has been the topic of several research reports. Wall Street Zen raised Clene from a “sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright reissued a “buy” rating on shares of Clene in a research report on Monday, October 19th. Finally, Weiss Ratings lowered shares of Clene from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, October 27th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.00.

About Clene

Clene Inc is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases. The company’s lead product candidate, CNM-Au8, is an investigational oral suspension containing catalytically active gold nanocrystals designed to support cellular energy production and reduce oxidative stress, with the goal of protecting and improving the function of nerve cells.

Clene has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), and has also investigated its potential applications in other neurodegenerative disorders.